JP2022095872A5 - - Google Patents

Download PDF

Info

Publication number
JP2022095872A5
JP2022095872A5 JP2022066071A JP2022066071A JP2022095872A5 JP 2022095872 A5 JP2022095872 A5 JP 2022095872A5 JP 2022066071 A JP2022066071 A JP 2022066071A JP 2022066071 A JP2022066071 A JP 2022066071A JP 2022095872 A5 JP2022095872 A5 JP 2022095872A5
Authority
JP
Japan
Prior art keywords
human insulin
insulin analogue
zinc complex
acylated derivative
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022066071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022095872A (ja
Filing date
Publication date
Priority claimed from JP2019503703A external-priority patent/JP7432361B2/ja
Application filed filed Critical
Publication of JP2022095872A publication Critical patent/JP2022095872A/ja
Publication of JP2022095872A5 publication Critical patent/JP2022095872A5/ja
Pending legal-status Critical Current

Links

JP2022066071A 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体 Pending JP2022095872A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201610625257 2016-08-02
CN201610625257.5 2016-08-02
CN201610779132.8 2016-08-31
CN201610779132 2016-08-31
JP2019503703A JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体
PCT/CN2017/095377 WO2018024186A1 (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019503703A Division JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体

Publications (2)

Publication Number Publication Date
JP2022095872A JP2022095872A (ja) 2022-06-28
JP2022095872A5 true JP2022095872A5 (enExample) 2022-12-08

Family

ID=61074099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503703A Active JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体
JP2022066071A Pending JP2022095872A (ja) 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019503703A Active JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体

Country Status (6)

Country Link
US (1) US10815287B2 (enExample)
EP (1) EP3495384A4 (enExample)
JP (2) JP7432361B2 (enExample)
CN (2) CN114478747B (enExample)
TW (1) TWI747929B (enExample)
WO (1) WO2018024186A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3747896A4 (en) * 2018-02-01 2021-11-24 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION OF ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOGUE AND MANUFACTURING PROCESS FOR IT
US20210032307A1 (en) 2018-02-09 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
BR112020023485A2 (pt) 2018-05-24 2021-03-30 Jiangsu Hengrui Medicine Co., Ltd. Métodos para preparar um precursor de insulina humana recombinante ou análogo da mesma, insulina humana recombinante ou análogo da mesma e análogo de insulina acilado
CA3122636A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
CN118894922A (zh) * 2019-12-30 2024-11-05 甘李药业股份有限公司 胰岛素衍生物
WO2022111642A1 (zh) * 2020-11-27 2022-06-02 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
CA3217734A1 (en) 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
CA3228912A1 (en) 2021-06-25 2022-12-29 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
EP4471053A1 (en) 2022-01-28 2024-12-04 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
CZ287945B6 (cs) * 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
CN1163574A (zh) * 1994-11-17 1997-10-29 伊莱利利公司 酰化的胰岛素类似物
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
JP4463814B2 (ja) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
EP2287184A3 (en) * 2003-08-05 2011-08-10 Novo Nordisk A/S Novel insulin derivatives
US20090074882A1 (en) * 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
MX2010009850A (es) * 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
US8935928B2 (en) * 2011-10-10 2015-01-20 Lockheed Martin Corporation Integrated air-cycle refrigeration and power generation system
WO2013086927A1 (zh) * 2011-12-15 2013-06-20 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
WO2017136834A1 (en) * 2016-02-05 2017-08-10 Memorial Sloan-Ketering Cancer Center Methods of differentiating stem cell-derived ectodermal lineage precursors

Similar Documents

Publication Publication Date Title
JP2022095872A5 (enExample)
JP2019526537A5 (enExample)
EP3463293B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, une insuline prandiale et/ou une hormone gastrointestinale, et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2011006428A5 (enExample)
JP2008528658A5 (enExample)
JP2019043957A5 (enExample)
RU2008143668A (ru) Производное инсулина
JP2016523241A5 (enExample)
JP2009536178A5 (enExample)
JP2010505741A5 (enExample)
RU2009122582A (ru) Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение
KR20240171196A (ko) pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
RU2012128547A (ru) Дважды ацилированные производные glp-1
JP2020143066A5 (enExample)
JP2012512901A5 (enExample)
US20190169257A1 (en) Acylated derivative of human insulin or analogue thereof
US20130331517A1 (en) Novel Polymer Derivative Of Cytidine Metabolic Antagonist
KR20240171197A (ko) pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
US20240158445A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
CA3084688A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JPH08508720A (ja) ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物
LU86697A1 (fr) Nouveaux derives de la calcitonine,leur preparation et leur utilisation comme medicaments
TW200927100A (en) Pharmaceutical composition for treating cataract
JP2009513562A5 (enExample)
JP2006513141A5 (enExample)